Decision Resources Group
260 Charles Street
22 articles with Decision Resources Group
Executive team addition reinforces increased investment in AI, machine learning and analytics-enabled solutions to improve patient access and outcomes
Decision Resources Group 2019 ePharma Physician® Report Finds U.S. Physicians Increasingly Too Busy to See Pharma Sales Reps
Primary Care Physicians Are Getting Particularly Tough for Reps to Reach; Docs Give Pharmas Higher Marks for Adding Value Online
Winners include Children's Hospital of Philadelphia, Nebraska Medicine and Springhill Medical Center
Decision Resources Group Launches CoPay Accumulator Product Providing Health Companies With Comprehensive CoPay Benefit Insights
Decision Resources Group is pleased to introduce CoPay Accumulator Threat Assessor as its latest product offering.
Decision Resources Group (DRG), a premier provider of healthcare data, analytics, and insights products and services, announced that Michael Weiss has been named Executive Vice President and General Counsel, effective October 1.
New Oncology Trends and Pipeline Tool Combines Decision Resources Group's Data Analytics Capabilities and Oncology Expertise
Decision Resources Group announced Davis Walp has joined as Chief Strategy Officer.
Decision Resources Group (DRG) announced at the AMCP Managed Care and Specialty Pharmacy Annual Meeting the launch of Healthbase.
Decision Resources Group (DRG), a premier provider of high-value data, analytics and insights products and services to the healthcare industry, has announced the launch of DRG Learning.
Decision Resources Group Release: A Focus on Specialty Pharmacy at Las Vegas Pharmaceutical Conference
Decision Resources Group Release: Keynote Speakers Announced for Sixth Annual Pinsonault Managed Markets Summit
Decision Resources Group Release: Competition for Early-Line Biologic Use Among Psoriasis Patients Intensifies as Humira Continues to Gain Ground on Enbrel
Decision Resources Group Release: Over the Next Decade, the Malignant Melanoma Drug Market Will Increase More Than Seven-Fold to $1.5 Billion in 2020
Decision Resources Group Release: Biosimilar Versions of TNF-alpha Inhibitors and Pegylated IFN-alpha Agents Will Save Healthcare Systems $5.3 Billion in 2020
Decision Resources, Inc. Finds Despite FDA Label Revisions Regarding LABA-Containing Drugs, Patient Share of LABA/ICS Combination Drugs Exceed Patient Share of Single-Agent ICS Drugs in Recently Treated Asthma Patients
Decision Resources, Inc. Release: The Majority of Surveyed U.S. Oncologists Identified FOLFIRINOX as the Most Efficacious Treatment for Advanced Pancreatic Cancer, When Compared to Other Currently Available Therapies